Kishoria 2020.

Study characteristics
Methods	Trial design: open‐label RCT with 2 parallel arms Type of publication: journal publication Setting: inpatient Recruitment dates: NR Country: India Language: English Number of centres: 1 Study purpose (treatment, prevention): treatment Trial registration number: NA Date of registration: NA
Participants	Number of participants (randomized/analyzed): 35/32 Age (mean): overall 38 (SD NR) years Males, n: overall 23 (72%) Severity of condition according to study definition: hospitalized, asymptomatic or mild symptoms Severity of condition according to WHO scale: 4 including people without symptoms Co‐morbidities: NR Virus detection performed at baseline (test‐positive at baseline): RT‐PCR (100%) Inclusion criteria: men or women, aged ≥ 18 years; tested positive after completion of standard care treatment for SARS‐CoV‐2 confirmed by RT‐PCR assay; mild symptoms or asymptomatic; no comorbidities affecting the patient's prognosis, rendering them at high risk; documented acceptance to participate by means of the execution of the informed consent Exclusion criteria: allergy or hypersensitivity to ivermectin or its inactive ingredients, or both; respiratory distress or requiring intensive care; used immunosuppressants (including systemic corticosteroids) in the last 30 days; known HIV infection with CD4 count < 300 cell/L; pregnancy or lactating women; medical conditions such as mal‐absorption syndromes affecting proper ivermectin absorption; autoimmune disease or decompensated chronic diseases, or both; uncontrolled, intercurrent diseases including renal impairment, hepatic impairment, symptomatic congestive heart failure, unstable chest angina, or heart arrhythmia; treated in any other study in the previous 30 days; concomitant administration of enzyme inducers (such as carbamazepine) that could affect the effectiveness of the drug and people receiving CYP3A4 substrates (such as statins) due to the risk of increased toxicity
Interventions	Details of intervention for relevant arms Type and dose: ivermectin 12 mg, single dose Route of administration: oral Treatment details of control group No treatment except standard of care Concomitant therapy: standard of care including hydroxychloroquine, vitamin C, and paracetamol administered in both study arms Duration of follow‐up: 6 days Treatment cross‐overs: none
Outcomes	Primary study outcome Negative throat swab report for SARS‐CoV‐2 conducted by RT‐PCR after 48 hours of day 1 of research therapy Relevant review outcomes reported Viral clearance at 3 days Additional study outcomes reported Viral clearance at 5 days Hospitalization status at end of study
Notes	Date of publication: August 2020 Sponsor/funding: NR Correspondence with the author team: author request sent (date of recruitment, reason for withdrawals, baseline characteristics regarding compensated comorbidities, reason for missing patients at 5 days); no response received from the author Information on ethics votum: no name of responsible ethics committee, reference number of proposal, or votum provided in publication. Sent author request; no response received